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Summary
Infant T-cell acute lymphoblastic leukaemia (iT-ALL) is a very rare and
poorly defined entity with a poor prognosis. We assembled a unique series
of 13 infants with T-ALL, which allowed us to identify genotypic abnor-
malities and to investigate prenatal origins. Matched samples (diagnosis/re-
mission) were analysed by single nucleotide polymorphism-array to identify
genomic losses and gains. In three cases, we identified a recurrent somatic
deletion on chromosome 3. These losses result in the complete deletion of
MLF1 and have not previously been described in T-ALL. We observed two
cases with an 11p13 deletion (LMO2-related), one of which also harboured
a deletion of RB1. Another case presented a large 11q141-11q232 deletion
that included ATM and only five patients (38%) showed deletions of
CDKN2A/B. Four cases showed NOTCH1 mutations; in one case FBXW7
was the sole mutation and three cases showed alterations in PTEN. KMT2A
rearrangements (KMT2A-r) were detected in three out of 13 cases. For
three patients, mutations and copy number alterations (including deletion
of PTEN) could be backtracked to birth using neonatal blood spot DNA,
demonstrating an in utero origin. Overall, our data indicates that iT-ALL
has a diverse but distinctive profile of genotypic abnormalities when com-
pared to T-ALL in older children and adults.
Keywords: infant, T-cell acute lymphoblastic leukaemia, genomic profile,
CNAs and in utero origin.
Acute lymphoblastic leukaemia (ALL) in children is a diverse
cancer characterized by associations between age at presenta-
tion, leukaemic subtype and recurrent genetic alterations
(Pui et al, 2004). ALL in infants is a rare subset often associ-
ated with KMT2A (also known as MLL) rearrangements
(KMT2A-r), a high leucocyte count at diagnosis, an imma-
ture or pro-B-cell lineage immunophenotype (CD10) and a
prenatal origin in utero (Ford et al, 1993; Biondi et al, 2000).
T-ALL is prevalent in older children. Though there is molec-
ular evidence that it can originate in utero (Ford et al, 1997;
Eguchi-Ishimae et al, 2008), it is a very rare disease in infants
(Biondi et al, 2000; Emerenciano et al, 2013). In contrast to
infant pro-B-lineage ALL with KMT2A-AFF1 fusion, in
which an in utero origin has been clearly demonstrated (Ford
et al, 1993; Gale et al, 1997), the developmental timing for
T-ALL is poorly defined.
In a previous study of T-ALL, we evaluated fifteen cases in
early childhood (age ≤24 months) for mutations that are
prevalent in infant ALL (pro-B) or T-ALL; NOTCH1 muta-
tions, although found less frequently than described for older
T-ALL paediatric cases, were the most frequent alterations
among these younger patients, followed by the KMT2A-r
(Emerenciano et al, 2006; Mansur et al, 2010).
The availability of a unique series of 13 infant T-ALL cases
(iT-ALL, ≤12 months) along with 12 remission samples allowed
us to determine the molecular profile of iT-ALL [copy number
alterations (CNAs)/gains and losses (loss of heterozygosity,
LOH)] using high-density Genome-Wide single nucleotide
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polymorphism (SNP) array accompanied by next generation
sequencing (NGS). We sought to investigate the possible prena-
tal onset of genetic abnormalities in iT-ALL using a ‘backtrack-
ing’ approach with neonatal blood spots (Guthrie cards).
Materials and methods
Patient samples
Seven Brazilian (BR1-BR7), one English (UK1) and five French
(FR1-FR5) iT-ALLs were included in this study (Supporting
Information). Material from diagnostic bone marrow (BM)
and/or peripheral blood (PB) was available from all patients
and remission samples (non-leukaemic) were collected for all
but one patient (BR4, who did not achieve remission). Guthrie
cards were obtained from four patients for use in our back-
tracking approach to trace prenatally acquired mutations.
Leukaemia characterization
In all cases, diagnosis of leukaemia was established by the
morphology of lymphoid cells and immunophenotyping by
flow cytometry using a previously established panel of mono-
clonal antibodies (Mansur et al, 2009). The immunological
classification of T-ALL was performed according to the Euro-
pean Group for the Immunological Characterization of Leu-
kaemias (EGIL) criteria (Bene et al, 1995).
T-ALL molecular screening
Diagnostic DNA samples from all iT-ALL cases were analysed
for the following gene abnormalities: NOTCH1, FBXW7,
PTEN, IL7R, KRAS, NRAS, STIL-TAL1 + , TLX3 + and
KMT2A-r (Weng et al, 2004; Mansur et al, 2009, 2012;
Zenatti et al, 2011; Emerenciano et al, 2013). T-cell receptor
gene rearrangements (TR-r; gamma/TRG, delta/TRD and
beta/TRB) were assessed using conditions recommended by
the BIOMED-2 Consortium (van Dongen et al, 2003; Lan-
gerak et al, 2012). Clonality was assessed by GeneScan pro-
filing (Applied Biosystems, Waltham, MA, USA) followed
by cloning of the products and Sanger sequencing. Sequences
were analysed using the Ig BLAST (www.ncbi.nlm.nih.gov/ig-
blast/) and the ImMunoGeneTics database (www.imgt.org).
Molecular analyses
Fluorescence in situ hybridization (FISH), CNA analyses,
NGS and backtracking of neonatal blood spots were all per-
formed as described in Data S1.
Results
Characterization of infant cases
Thirteen iT-ALL cases were investigated. The median age
at diagnosis was 9 months, there was no predominance of
gender, and a high leucocyte count (≥50 9 109/L) was
observed in 12 out of 13 cases (Table SI). Immunopheno-
type analyses performed on all 13 diagnostic cases revealed
that six patients presented T-IV profile, five cases T-III
and for the other two cases, one presented T-I and the
other a T-II profile. The T-I profile case (BR4) also
expressed two classical myeloid markers CD13 and CD33
which, according to previously published criteria (Coustan-
Smith et al, 2009), suggests an Early T-cell Progenitor
(ETP) leukaemia.
Molecular analysis
The main results from the targeted molecular analyses car-
ried out on the iT-ALL samples are shown in Table I.
The 13 diagnostic infant samples were screened for the
known recurrent mutations in T-ALL, including NOTCH1,
FBXW7, PTEN and IL7R (detailed mutation data is shown in
Table SII), as well as KRAS, NRAS mutations, STIL-TAL1
fusion and the presence of TLX3. Results showed four cases
were mutated for NOTCH1, two being mutated in the HD
domain only (BR1 and FR4), one in the PEST only (BR6)
and one (FR3) with mutations in both HD and PEST.
Patient BR1 presented a combined NOTCH1/FBXW7 muta-
tion. One case (FR5) presented a sole FBXW7 mutation.
Three cases presented PTEN alterations (FR1 and FR3 as
mutations and BR6 as CNA/deletion) and all patients were
IL7R, KRAS and NRAS wild type (WT). KMT2A-r was
confirmed in three cases (two KMT2A-MLLT1 and one
KMT2A-MLLT4) and, distinct from childhood T-ALL, we
observed no infants with either STIL-TAL1+ or TLX3+. TR-r
analyses were performed and all but one case (BR4) showed
clonal rearrangements (Table I).
SNP-array and FISH data
All diagnostic samples were analysed by SNP-array to iden-
tify genomic losses (LOH) and gains (Table SIII), although
one sample (BR1) had a low contrast quality control (CQC,
Table SIV). The DNA from this sample was extracted from
diagnostic BM slides, from which we were able to identify
two alterations: TR monoclonal rearrangements and
CDKN2A homozygous deletion. Both results were confirmed
using polymerase chain reaction (PCR) and quantitative PCR
(Q-PCR) approaches.
Among the CNAs identified by SNP-array, we highlight
genes considered as ‘drivers’ of the leukaemic process i.e.
those genes already causally implicated in the process of
oncogenesis (Table SIII). A recurrent 3q2532 deletion was
observed in three out of 13 cases (BR4, BR6 and BR7;
Fig 1A) that encompassed MLF1 (myeloid leukaemia factor
1), a negative regulator of cell cycle progression which func-
tions upstream of the tumour suppressor TP53 (Yoneda-Kato
et al, 2005). For these 3 cases the deletion range varied
between 528,000 bp and 610,000 bp but each deletion
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encompassed the entire MLF1 gene. MLF1 deletion was con-
firmed by FISH on case BR6, using a combination of MLF1
and CDKN2A in-house probes (Fig 1B). For the same
patient, we also used FISH to confirm both KMT2A-r and
PTEN deletion (Fig 1B). Using a SP60-array approach, we
could not detect deletion of MLF1 in over 90 European and
Brazilian cases of childhood and adolescent T-ALL (unpub-
lished data).
SNP-array analyses also revealed one case (UK1) to har-
bour small deletions in KMT2A (11q23) and MLLT4 genes
(6q27) (Fig 1C) and, because MLLT4 is recognized as a clas-
sical KMT2A translocation partner gene, we used FISH to
search for a potential KMT2A-r. Consequently, we first
detected a KMT2A deletion using the LSI MLL (KMT2A)
Dual Colour, Break Apart probe (Fig 1D) and then, using
in-house FISH probes for both KMT2A and MLLT4, we con-
firmed the occurrence of KMT2A-r (Fig 1D).
In common with non-infant paediatric T-ALL, two of our
infant cases revealed an 11p13del (BR3 and BR5; Fig S1), a
deletion first described in T-ALL at a frequency of 4% that
also involves region 11p12 (Van Vlierberghe et al, 2006).
Two other studies on childhood T-ALL have identified the
same deletion (Mullighan et al, 2008; Szczepanski et al,
2011). A large 11q14-q23 deletion (Fig S1) including ‘driver’
genes (ATM, EED) was observed in one case (FR4) while in
another, (BR5), we observed a 13q142 deletion that involved
the RB1 gene (Fig S2).
Further analysis of our iT-ALL cohort revealed a lower
frequency of CDKN2A deletions than found in paediatric
T-ALL. These deletions occur in 70% of T-ALL (Mullighan
et al, 2008), but in our study only 38% of iT-ALL cases
harboured this deletion (Fig 2).
Table I. Clinical-molecular characterization of infant T-cell acute lymphoblastic leukaemia cases.
Patient
ID
Age
(months) Gender EGIL TR-r NOTCH1 FBXW7 PTEN IL7R
KRAS/
NRAS
STIL-
TAL1 KMT2A-r Outcome
BR1 12 Male T-IV TRG & D HD Mut Mut WT WT WT Neg Neg Deceased
BR2 8 Male T-IV TRG, D & B WT WT WT WT WT Neg MLLT1 Deceased
BR3 6 Female T-IV TRG, D & B WT WT WT WT WT Neg Neg Deceased
BR4* 7 Female T-I No Rear WT WT WT WT WT Neg Neg Deceased
BR5* 11 Male T-II TRG, D & B WT WT WT WT WT Neg Neg Deceased
BR6* 7 Female T-III TRG, D & B PEST Mut WT WT/del WT WT Neg MLLT1 Alive/CCR
BR7* 8 Male T-III TRD WT WT WT WT WT Neg Neg Deceased
UK1 9 Male T-III TRG WT WT WT WT WT Neg MLLT4 Deceased
FR1 9 Female T-III TRG & D WT WT Mut WT WT Neg Neg Alive/CCR
FR2 11 Female T-IV TRG, D & B WT WT WT WT WT Neg Neg Deceased
FR3 12 Male T-III TRG & D HD/PEST Mut WT Mut WT WT Neg Neg Deceased
FR4 11 Female T-IV TRG, D & B HD Mut WT WT WT WT Neg Neg Deceased
FR5 9 Female T-IV TRG & D WT Mut WT WT WT Neg Neg Alive/CCR
ID, identification; EGIL, European Group for the Immunological Characterization of Leukaemias classification; TR-r, T-cell receptor rearrange-
ments; Mut, mutated; WT, wild type; HD, Heterodimerization Domain; PEST, polypeptide enriched in proline, glutamic acid, serine and thre-
onine domain; Neg, negative; Pos, positive; KMT2A-r, KMT2A rearranged, KMT2A (also known as MLL); MLLT1 (also known as ENL); MLLT4
(also known as AF6); CCR, complete continuous remission. PEST and TAD (transactivation domain) are both designated as PEST domain only.
*Patients with available Guthrie cards (GC or neonatal blood spots).
Table II. Main genomic findings observed in our series of infant
T-cell acute lymphoblastic leukaemia cases.
Patient
ID Main CNAs Gene Alterations
BR1 CDKN2A/B del NOTCH1 and FBXW7 mutations
BR2 IKZF1 del KMT2A-MLLT1
ETV6 del
FLT3 del
BR3 11p13del/LMO2
over
BR4 MLF1 del AIM1, SLC35D1, PIK3CB, DTHD1,
TIE1,
SH3BP2, MLLT4, MZF1, EP300, TLK2,
NOL8, PIDD1, RPL3, TCTN2, CHFR,
KAT6B,
TNK2, DLX6, BPTF, CNGB1, TUSC1
and PDLIM5
BR5 11p13del/LMO2
over
RB1 del
BR6 MLF1 del KMT2A-MLLT1
PTEN del NOTCH1 mutation
BR7 MLF1 del
UK1 MLLT4 del KMT2A-MLLT4
KMT2A del
FR1 CDKN2A/B del PTEN mutation
FR2 CDKN2A/B del
FR3 CDKN2A/B del NOTCH1 and PTEN mutations
FR4 11q14-q23del/ATM
and EED
NOTCH1 mutation
FR5 CDKN2A/B del FBXW7 mutation
ID, identification; CNAs, copy number alterations; del, deletion;
over, overexpression.
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Copy number assays – Q-PCR and promoter
methylation status of CDKN2A
In order to confirm the CDKN2A SNP-array data (Fig 2A)
on the five patient samples showing 9p213 deletions, we per-
formed real-time Q-PCR assays on all 13 diagnostic samples
using three different copy number probes located across the
gene. In Fig 2B we highlight in particular the SNP analysis
for case BR1, for which the array data presented lower CQC
compared with the other 12 cases. In this experiment, we
used two normal control DNAs (2 CDKN2A copies), one
heterozygous deleted control (1 CDKN2A copy) and DNA
from the cell line RPMI-8402 as a homozygous deleted con-
trol, (0 CDKN2A copies). Evaluation of the CDKN2A status
in the other iT-ALL cases is shown in Fig 2C and Fig S3.
As the majority of our cases did not present a visible
CDKN2A gene deletion, we explored a potential alternative
pathway for CDKN2A inactivation, i.e. occurrence of
CDKN2A promoter methylation. Accordingly, we performed
methylation-specific PCR on all 13 iT-ALL patient samples
and on two control cell lines: RAJI and HL60 (Supporting
Information). Conventional Sanger sequencing of the PCR
amplicons established the correct genomic location within
Fig 1. Chromosome aberrations in infant T-cell acute lymphoblastic leukaemia. (A) Copy number analysis of chromosome 3. The deleted region
of chromosome 3 (MLF1 included) is highlighted in grey for three of our patients (BR4, BR5 and BR6); (B) MLF1 (spectrum green) and
CDKN2A (spectrum orange) in-house probes confirming MLF1 deletion in patient BR6 & KMT2A Break Apart (spectrum orange/spectrum
green) and PTEN (biotin-Cy5/turquoise) probes showing KMT2A-r and single copy of PTEN in patient BR6. (C) and (D) SNP-array and FISH
analysis of patient UK1. (C) The grey boxes highlight the deleted areas in chromosomes 6 and 11, respectively; (D) FISH using LSI MLL
(KMT2A) Dual Colour, Break Apart Rearrangement probe (spectrum orange/spectrum green) showing the KMT2A deletion (one orange signal
missing); and in-house probes, both designed in non-deleted areas of MLLT4-Cy3 and KMT2A-spectrum green, confirming the KMT2A-r
between these two genes.
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the CDKN2A exon 1 CpG island and confirmed bisulfite
modification of the unmethylated cytosine to uracil. As
expected, the DNA from the RAJI cell line produced a strong
band with methylated primers, while DNA from the HL60
cell line generated a strong band with unmethylated primers.
None of the patients revealed a methylated profile for
CDKN2A (Fig S4), suggesting that methylation was not an
alternative mode of CDKN2A inactivation in these cases.
NGS data
Due to the paucity of available DNA from most infants we
were unable to perform NGS on all cases and consequently
prioritized those cases for which Guthrie Cards were avail-
able.
Patient BR4 presented an ETP-profile with no typical
T-ALL molecular alterations. We performed whole exome
sequencing (WES) on DNA isolated from diagnostic
material, however this patient did not achieve remission and
therefore no germline material was available for matched
analyses. In order to uncover somatic alterations acquired
by the leukaemic clone, we filtered out mutations listed
in the dbSNP and/or 1000genomes databases (http://
www.ncbi.nlm.nih.gov/snp/; http://www.1000genomes.org/)
and identified a total of 832 single nucleotide variations
(SNVs) and 872 insertions or deletions (indels) at diagnosis.
In the BR4 diagnostic sample, after respectively filtering
the data by read depth (between 20–250x), coding areas
only and deleterious/possibly damaging at protein level (VEP-
Ensembl; http://www.ensembl.org/Homo_sapiens/Tools/VEP),
we detected 176 SNVs and 272 indels. We decided to
focus particularly on 22 affected genes, which have an estab-
lished causal role in oncogenesis and could therefore be con-
sidered as ‘drivers’ of leukaemia. For SNVs we chose AIM1,
SLC35D1, PIK3CB, DTHD1, TIE1, SH3BP2, MLLT4, MZF1,
EP300, TLK2, NOL8, PIDD1, RPL3, TCTN2 and CHFR and
for indels we chose; KAT6B, TNK2, DLX6, BPTF, CNGB1,
TUSC1 and PDLIM5 (Fig 3A and Table SV). Due to the pau-
city of available patient material, we simply confirmed
selected heterozygous point mutations and indels by Sanger
Fig 2. Genomic copy number analysis of
CDKN2A. (A) SNP-array analysis of 9p213 for
the 13 infant T-cell acute lymphoblastic leukae-
mia patients, highlighting cases harbouring
CDKN2A/B deletions (BR1, FR1, FR2, FR3 and
FR5), the deleted areas are shown in blue; and
(B) and (C) Q-PCR copy number analysis with
three different assays for CDKN2A. (B) The
charts show patient BR1 as homozygous
deleted, also included in the analysis are one
heterozygous control, two normal controls and
RPMI-8402 (CDKN2A homozygous deleted).
(C) Q-PCR copy number data for patient UK1
and all French cases showing CDKN2A
heterozygous deletion for patients FR1, FR2
and FR5 and homozygous deletion for FR3,
FR4 and UK1 are both CDKN2A wild-type
(WT).
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sequencing in 14 out of the 22 chosen genes, i.e. AIM1,
PIK3CB, DTHD1, TIE1, SH3BP2, MLLT4, MZF1, EP300,
TLK2, PIDD1, RPL3, KAT6B, BPTF and PDLIM5 (data not
shown).
For patient BR6 we used a whole genome sequencing
(WGS) approach to precisely determine the CNAs break-
points with the aim of using this data for subsequent blood
spot backtracking analyses. We filtered the WGS data by
somatic alterations only, somatic P ≤ 005 and exonic areas
only and identified 145 mutations (SNVs and indels). Here,
we particularly highlight 15 genes that were affected by novel
mutations, i.e. mutations not been previously described in
reference databases. The genes were: CCDC162P, ADAMTS7,
IGSF3, LOC100506990, SPATA31C2, NOS2, ANKRD20A5P,
HNRNPCL1, TMEM51-AS1, LOC388692, KCTD18,
LOC100506060, MLLT10P1, OLIG1 and NOTCH1 (Fig 3B
and Table SVI). Table II summarises the main genomic
abnormalities observed in our rare series of iT-ALL.
Backtracking aberrations to an origin in utero
We also sought to investigate the early onset of genetic abnor-
malities by backtracking to birth the aberrations already pre-
sent at diagnosis. We obtained archived Guthrie cards of four
of the patients (BR4, BR5, BR6 and BR7). Potential clonal
markers among these four patients included: a rearranged
TRD (BR7); a KMT2A-r, a PTEN deletion and a NOTCH1
indel (all in BR6); and 11p13 and RB1 deletions (both in BR5).
The fourth case (BR4) harboured 22 mutations affecting can-
cer-associated genes and aMLF1 deletion as its only CNA.
We previously determined MLLT1 as the partner for
KMT2A-r in patient BR6 and subsequently the breakpoint
sequence of this rearrangement (Emerenciano et al, 2013),
which allowed us to design patient-specific primers to
interrogate this rearrangement in the Guthrie card DNAs.
From ten individual Guthrie card DNAs examined for BR6,
one was KMT2A-MLLT1+ (Fig 4A). To investigate the
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Fig 3. Principal mutations detected by next generation sequencing in patients BR4 and BR6. (A) List of the relevant genes affected by mutations
(SNVs and indels) for BR4 at diagnosis. Guthrie card DNAs (GC) from patient BR4 were not submitted to WES analysis but were subsequently
used to check the somatic versus germline status of the mutations detected at diagnosis. (B) Somatic alterations (SNVs and indels) detected by
WGS in BR6 diagnostic DNA. A remission (germline) sample confirmed the somatic status of all the alterations listed. For both (A) and (B),
we highlight the mutations affecting coding areas only. Different colours discriminate SNVs (WES-blue, WGS-green) from indels (WES-red,
WGS-orange). **WES was not performed on this material. Guthrie card DNAs were investigated by conventional Sanger sequencing. SNV, single
nucleotide variation; indel, insertion or deletion; WES, whole exome sequencing; WGS, whole genome sequencing; WT, wild-type.
Fig 4. Prenatally acquired alterations in patient BR6. (A) KMT2A-MLLT1 Sanger sequencing of BR6 diagnostic and Guthrie card DNAs, showing
that the patient presented an identical KMT2A-MLLT1 breakpoint at both time points. Top panel: GRCh38 Primary Assembly as reference for
both gene sequences (KMT2A/NC_00001110 and MLLT1/NC_00001910). M-H = micro-homologies. (B) Cloning experiment detecting
NOTCH1-PEST deletion in the Guthrie card. The top sequence shows the NOTCH1 NCBI Reference Sequence – NM_0176173 – used to locate
both mutations. The base pairs and amino acids deleted are highlighted in the red boxes. The first box represents sequenced Guthrie card DNA
(colony 27) from patient BR6 harbouring both NOTCH1-PEST deletions, i.e. c.7244_7246delCAC and c.7280delG and the second box shows BR6
diagnostic DNA (colony 61) also presenting both deletions. The c.7244_7246delCAC causes a Proline (P) deletion (# in the protein sequence
p.2415delP), whereas c.7280delG generates a premature stop codon (*). (C) PTEN deletion breakpoint in patient BR6 diagnostic and Guthrie card
DNAs. Primers 1 and 3 were used for the first PCR reaction and 2 and 3 for the semi-nested one. Sanger sequencing data shows the deletion
breakpoint present in both diagnostic (top, BR6 Diagnostic DNA) and also in one of ten Guthrie card DNAs tested (bottom, BR6 Guthrie card
DNA-GC5). GRCh37/hg19 was the reference for these analyses.
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prenatal origin of the NOTCH1 indel detected at diagnosis
we also performed a specific semi-nested PCR experiment. In
total, we analysed 1200 cloned sequences from the ten blood
spot DNAs and identified a single clone with the same
NOTCH1-PEST deletion that was present at diagnosis
(c.7280delG). Unexpectedly, this clone also harboured a new
mutation found 36 base pairs upstream from c.7280delG,
(i.e. c.7244_7246delCAC, Fig 4B). This 3 base-pair CAC dele-
tion was also detected alone in 15/1200 Guthrie card clones.
Although this deletion was not initially discovered in
the bulk DNA analysis of diagnostic material, after cloning
the NOTCH1-PEST amplicon from BR6 diagnostic DNA, we
found 1/100 clones with both c.7244_7246delCAC and
c.7280delG (Fig 4B). Furthermore, as expected for a
heterozygous mutation, we observed 50/100 clone sequences
with the c.7280delG only. These results suggest that
NOTCH1 c.7280delG and c.7244_7246delCAC both occurred
prenatally and that the latter potentially occurred (indepen-
dently) in a cell that did not represent the major clone at
diagnosis.
We used WGS to determine the precise breakpoint for
the PTEN deletion detected by SNP-array in the BR6
diagnostic sample. The breakpoint in this diagnostic mate-
rial was cloned using specific primers designed from the
WGS coordinates (Fig 4C). Subsequently, we used a semi-
nested approach to interrogate the ten DNAs from the
Guthrie cards of this patient. One positive DNA (GC5)
was identified and Sanger sequenced, confirming that the
PTEN deletion in the diagnostic sample was present at
birth (Fig 4C). To our knowledge this is the first observa-
tion of a gene deletion being identified in a neonatal
blood spot.
We next tested the blood spot DNAs from patient BR4 by
conventional PCR for the 14 WES mutations validated in the
diagnostic DNA. Unfortunately, this patient did not achieve
remission and died shortly after diagnosis. All 14 mutations
were found in the four Guthrie card DNAs tested (Fig 4A),
thus confirming their presence before birth. Nevertheless, we
cannot confirm whether these were acquired as somatic
mutations in utero solely in haematopoietic cells or were
indeed germline mutations.
For patient BR5 we were unable to clone the deletion
breakpoints for 11p13 (Fig S1) or for a large heterozygous
deletion on chromosome 13 downstream of exon 1 in the
tumour suppressor gene RB1 (Fig S2A). However, using
Q-PCR copy number analysis (Figs S2B and C) we were able
to detect the loss of intron 17 of RB1 in diagnostic and BR5
Guthrie card DNA while intron 1 was undeleted in both.
The heterozygous deletion was variably detected in all
Guthrie DNAs tested, but not in remission DNA, again sug-
gesting a potential in utero origin for this aberration.
Finally, the TRD rearrangement identified in patient BR7
contained a very small V(N)J junction which, although
found to be present in its neonatal blood spot, could not be
confirmed as being patient-specific with adequate specificity.
Discussion
A novel finding in this unique series of iT-ALL was the loss
of 3q2532 resulting in the complete deletion of MLF1, not
previously described in T-ALL nor in acute leukaemias as a
deletion. In addition, we have interrogated over 90 Euro-
pean and Brazilian cases of childhood and adolescent T-ALL
and we were not able to detect this deletion (unpublished
data). These data support the notion that deletion of MLF1
may represent a specific marker of iT-ALL. This gene was
originally identified as a partner of NPM1 in the transloca-
tion t(3;5)(q25;q34), commonly found in acute myeloid leu-
kaemia (AML) and myelodysplastic syndromes and has been
shown to play a key role in the leukaemogenesis of these
neoplasias (Bras et al, 2012). MLF1 plays a regulatory role
in TP53 activity, stabilizing the protein by suppressing its
E3 ubiquitin ligase (RFWD2) (Yoneda-Kato et al, 2005).
Based on these findings we suggest that this gene deletion
may have an oncogenic function because TP53 degradation
is triggered by E3 ubiquitin ligase activity in the absence of
MLF1. Hence, we hypothesize that MLF1 could act as a
recurrent tumour suppressor gene in iT-ALL, however func-
tional studies will be needed to elucidate its role in leukae-
mogenesis.
We provide evidence that iT-ALL, in common with infant
pro-B ALL (Ford et al, 1993; Gale et al, 1997) and at least
some cases of T-ALL in childhood (Ford et al, 1997; Eguchi-
Ishimae et al, 2008), can be initiated in utero. Definitive data
was obtained on one patient (BR6). The neonatal blood spots
archived for BR6 harboured the clonotypic KMT2A-MLLT1
fusion sequence, as well as the NOTCH1 mutation and the
PTEN deletion, albeit at low frequencies. Additionally, we
found evidence suggesting independent deletions in the PEST
domain of NOTCH1. Given the very young age of the
patient this is not surprising, nevertheless these data suggest
not only a prenatal initiation of iT-ALL but significant clonal
evolution prior to birth, i.e. sequential acquisition of several
mutations. This might help explain the presentation features
of high white cell count but very young age (BR6,
7 months). In contrast, for children who present with ETV6-
RUNX1 pre-B ALL at an older age, usually with low or mod-
est leukaemic burdens, the fusion gene appears to be the only
prenatal ‘driver’ event (Ma et al, 2013).
Our series of iT-ALL displayed a lower frequency of all
the major recurrent gene alterations and CNAs found in
childhood T-ALL (Mullighan et al, 2007; Andersson et al,
2015). PTEN mutations and/or deletions appeared to be the
only abnormality that occurred with the expected frequency
(9-20%) (Gutierrez et al, 2009; Mendes et al, 2014). We also
observed a lower frequency of alterations affecting CDKN2A
than has been found in childhood leukaemia, suggesting that
its role in iT-ALL leukaemogenesis may be less important
than in childhood T-ALL or B lineage ALL (Mullighan et al,
2007). An absence of CNAs was recently reported in
KMT2A-r infant ALL (Andersson et al, 2015).
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Previous literature reported a single case with concomitant
KMT2A deletion and KMT2A-MLLT4 rearrangement, these
abnormalities both being present in the diagnostic sample of
a three-year-old child with T-ALL (De Braekeleer et al,
2010). Therefore, patient UK1 is the second reported T-ALL
case with these KMT2A alterations combined. Deletion of
KMT2A has also been described in cases of precursor B
infant ALL with KMT2A-r (Andersson et al, 2015).
A deletion in the classical tumour suppressor gene, RB1,
was observed in one (BR5) of our 13 cases. RB1 deletions are
described at a frequency of 6-10% for both B-cell precursor
ALL and T-ALL in children and adults (Okamoto et al,
2010; Schwab et al, 2013). Deletion at 11p12p13 can act to
transcriptionally activate the LMO2 gene, a classic oncogene
in T-cell leukaemogenesis (Lecuyer & Hoang, 2004). Dele-
tions affecting locus 11p13 were identified in two of our
cases, including BR5, suggesting that this deletion could lead
to LMO2 activation and contribute to the development of
iT-ALL. Unfortunately, cells were not available from these
patients to investigate LMO2 expression. The 11q141-
q232del Chr11q/ATM deletions present in patient FR4 have
been reported in 30% of chronic lymphocytic leukaemia
cases (Edelmann et al, 2012; Skowronska et al, 2012) and at
a lower rate in ALL (Schwab et al, 2013).
Patient BR4 presented an ETP-profile with no typical T-
ALL molecular alterations. Hence, we performed WES analy-
ses with a view to uncovering potential ‘driver’ alterations
that could account for the emergence of leukaemia. By
grouping our 22 highlighted genes according to the hall-
marks of cancer (Hanahan & Weinberg, 2011), we uncovered
roles including sustaining proliferative signalling, activating
invasion and metastasis, resisting cell death and evading
growth suppressors. Furthermore, three groups of mutations
characteristic of ETP-ALL (RAS signalling, haematopoietic
and epigenetic regulators) (Zhang et al, 2012) were also
observed in our case. Some of the aberrant genes that we
uncovered do not yet have their functions fully elucidated.
Given the ease of detection of mutations in the neonatal
blood spots of this patient, compared to our other cases, we
speculate that they may be germline mutations. It is of inter-
est that an excess of germline variations in KMT2A-r nega-
tive infant leukaemia has been described by Valentine et al
(2014), who suggested that such cases may well be enriched
for rare coding and deleterious germline variations in cancer-
associated genes. The authors postulate that such variations
might comprise some proportion of the expected functional
imbalance characteristically observed in cancer. This notion
aligns with our own KMT2A-r negative case that also did not
reveal any of the expected ETP somatic mutations, such as
SETD2 or EZH2. Nevertheless EP300, a known ‘driver’ for
ETP-ALL (Zhang et al, 2012), was carried as a suspected
germline mutation in patient BR4.
In summary, we have analysed the genomic abnormalities
in a unique series of a rare subtype of paediatric leukaemia –
T-ALL in infants. The genotypes or mutational spectra are
varied but, overall, different from those of T-ALL in older
children and adults. A novel aberration (for acute leukae-
mia), MLF1 deletion, was present as a recurrent abnormality
in three of 13 cases. Finally, we have provided evidence that
some of the genetic abnormalities, including a PTEN dele-
tion, were accrued prenatally.
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